Gene expression in cisplatin ototoxicity and protection with p53 inhibitor

Journal of Otology

Volumn 4, Issue 2, 2009, Pages 61-70

  Ding, Da–lian ^a,c,d   Ping, Wang ^a,b   Haiyan, Jiang ^a   Coling, Donald ^a   Salvi, Richard ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^d THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cisplatin; cochlea; gene expression; hair cells; ototoxicity; p53; Pifithrin a; spiral ganglion neurons

Indexed keywords

EID: 84894604322     PISSN: None     EISSN: 16722930     Source Type: Journal    
DOI: 10.1016/S1672-2930(09)50016-5     Document Type: Article

References (75)

1. Estrem, S.A., Babin, R.W., Ryu, J.H., et al. Cis–diammi – nedi–chloroplatinum(II) ototoxicity in the guinea pig. Otolaryngol Head Neck Surg 89 (1981), 638–645.
2. Grammatica, L., Achille, G., Cortese, M., Casaula, M., Mininni, F., Cisplatin ototoxicity: the experience of the Institute of Oncology in Bari. Acta Otorhinolaryngol Ital 12 (1992), 383–388.
3. Jones, T.W., Chorpa, S., Kaufman, J.S., et al. Cis–diammin – edichloroplatinum (II) –induced acute renal failure in the rat: enzyme histochemical studies. Toxicol Pathol 13 (1985), 296–305.
4. Ma, C.L., Cis–diamminedichloroplatinum cochlear toxicity. Zhonghua Er Bi Yan Hou Ke Za Zhi 25 (1990), 199–201 254.
5. Marco–Algarra, J., Basterra, J., Marco, J., Cis–diaminedichloro platinum ototoxicity. An experimental study. Acta Otolaryngol 99 (1985), 343–347.
6. Ding, D., Qi, W., Zhang, M., et al. Cisplatin and its ototoxicity. Chinese Journal of Otology 6:2 (2008), 125–133.
7. Siddik, Z.H., Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003), 7265–7279.
8. Alam, S.A., Ikeda, K., Oshima, T., et al. Cisplatin–induced apoptotic cell death in Mongolian gerbil cochlea. Hear Res 141 (2000), 28–38.
9. Markman, M., Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf 2 (2003), 597–607.
10. Meijer, C., de Vries, E.G., Marmiroli, P., et al. Cisplatin–induced DNA–platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 20 (1999), 883–887.
11. Oldenburg, J., Fossa, S.D., Dahl, A.A., Scale for chemotherapy–induced long–term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res 15 (2006), 791–800.
12. Schweitzer, V.G., Hawkins, J.E., Lilly, D.J., et al. Ototoxic and nephrotoxic effects of combined treatment with cis–diamminedichloroplatinum and kanamycin in the guinea pig. Otolaryngol Head Neck Surg 92 (1984), 38–49.
13. Screnci, D., McKeage, M.J., Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J Inorg Biochem 77 (1999), 105–110.
14. Clerici, W.J., Hensley, K., DiMartino, D.L., et al. Direct detection of ototoxicant–induced reactive oxygen species generation in cochlear explants. Hear Res 98 (1996), 116–124.
15. Dehne, N., Lautermann, J., Petrat, F., et al. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. Toxicol Appl Pharmacol 174 (2001), 27–34.
16. Kopke, R.D., Liu, W., Gabaizadeh, R., et al. Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin–induced damage of auditory hair cells. Am J Otol 18 (1997), 559–571.
17. Ravi, R., Somani, S.M., Rybak, L.P., Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol 76 (1995), 386–394.
18. Rybak, L.P., Whitworth, C., Somani, S., Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope 109 (1999), 1740–1744.
19. Sueishi, K., Mishima, K., Makino, K., et al. Protection by a radical scavenger edaravone against cisplatin–induced nephrotoxicity in rats. Eur J Pharmacol 451 (2002), 203–208.
20. Huang, T.S., Shu, C.H., Lee, C.C., et al. In vitro evaluation of GL331’s cancer cell killing and apoptosis–inducing activity in combination with other chemotherapeutic agents. Apoptosis 5 (2000), 79–85.
21. Rybak, L.P., Ravi, R., Somani, S.M., Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: antioxidant system. Fundam Appl Toxicol 26 (1995), 293–300.
22. Watanabe, K., Inai, S., Jinnouchi, K., et al. Expression of caspase–activated deoxyribonuclease (CAD) and caspase 3 (CPP32) in the cochlea of cisplatin (CDDP) –treated guinea pigs. Auris Nasus Larynx 30 (2003), 219–225.
23. Machleidt, T., Geller, P., Schwandner, R., et al. Caspase 7–induced cleavage of kinectin in apoptotic cells. FEBS Lett 436 (1998), 51–54.
24. Tsukasaki, N., Whitworth, C.A., Rybak, L.P., Acute changes in cochlear potentials due to cisplatin. Hear Res 149 (2000), 189–198.
25. Tsuruya, K., Ninomiya, T., Tokumoto, M., et al. Direct involvement of the receptor–mediated apoptotic pathways in cisplatin–in–duced renal tubular cell death. Kidney Int 63 (2003), 72–82.
26. Devarajan, P., Savoca, M., Castaneda, M.P., et al. Cisplatin–in–duced apoptosis in auditory cells: role of death receptor and mitochondrial pathways. Hear Res 174 (2002), 45–54.
27. Ding, D., Jiang, H., Wang, P., et al. Cell death after co–administration of cisplatin and ethacrynic acid. Hear Res 226 (2007), 129–139.
28. Basu, A., Akkaraju, G.R., Regulation of caspase activation and cis–diamminedichloroplatinum (II) –induced cell death by protein kinase C. Biochemistry 38 (1999), 4245–4251.
29. Fuchs, J., Wenderoth, M., von Schweinitz, D., et al. Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma. Cancer 83 (1998), 2400–2407.
30. Persons, D.L., Yazlovitskaya, E.M., Cui, W., et al. Cisplatin–induced activation of mitogen–activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal–regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 5 (1999), 1007–1014.
31. Persons, D.L., Yazlovitskaya, E.M., Pelling, J.C., Effect of extracellular signal–regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 275 (2000), 35778–35785.
32. Sanchez–Perez, I., Perona, R., Lack of c–Jun activity increases survival to cisplatin. FEBS Lett 453 (1999), 151–158.
33. Choi, B.K., Choi, C.H., Oh, H.L., et al. Role of ERK activation in cisplatin–induced apoptosis in A172 human glioma cells. Neurotoxicology 25 (2004), 915–924.
34. DeHaan, R.D., Yazlovitskaya, E.M., Persons, D.L., Regulation of p53 target gene expression by cisplatin–induced extracellular signal–regulated kinase. Cancer Chemother Pharmacol 48 (2001), 383–388.
35. Hayakawa, J., Ohmichi, M., Kurachi, H., et al. Inhibition of extracellular signal–regulated protein kinase or c–Jun N–terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 274 (1999), 31648–31654.
36. Park, S.A., Park, H.J., Lee, B.I., et al. Bcl–2 blocks cisplatin–induced apoptosis by suppression of ERK–mediated p53 accumulation in B104 cells. Brain Res Mol Brain Res 93 (2001), 18–26.
37. Woessmann, W., Chen, X., Borkhardt, A., Ras–mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother Pharmacol 50 (2002), 397–404.
38. Ding, D., Lanzoni, I., Corbacelli, E., et al. PD98059 protects cochlear hair cells from cisplatin. Abstr Assoc Res Otolaryngol, 2004.
39. Hershberger, P.A., McGuire, T.F., Yu, W.D., et al. Cisplatin potentiates 1, 25–dihydroxyvitamin D3–induced apoptosis in association with increased mitogen–activated protein kinase kinase kinase 1 (MEKK–1) expression. Mol Cancer Ther 1 (2002), 821–829.
40. Kalinec, F., Kalinec, G., Boukhvalova, M., et al. Establishment and characterization of conditionally immortalized organ of corti cell lines. Cell Biol Int 23 (1999), 175–184.
41. Zhang, M., Liu, W., Ding, D., et al. Pifithrin–alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin–induced apoptosis. Neuroscience 120 (2003), 191–205.
42. Ding, D., Stracher, A., Salvi, R., Leupeptin protects cochlear and vestibular hair cells from gentamicin ototoxicity. Hearing Research 164 (2002), 115–126.
43. Gonzalez, S., Tercero, J.M., Matilla, A., et al. Cis–Dichloro (diaminosuccinate diethyl ester) palladium (II) as Pd (II)/Pt (II) model compound for DNA–binding and antitumor properties: solution equilibria of their aqua–, hydroxo–, and/or chloro–species. J Inorg Biochem 61 (1996), 261–272.
44. Gonzalez, V.M., Fuertes, M.A., Alonso, C., et al. Is cisplatin–induced cell death always produced by apoptosis?. Mol Pharmacol 59 (2001), 657–663.
45. Kartalou, M., Essigmann, J.M., Mechanisms of resistance to cisplatin. Mutat Res 478 (2001), 23–43.
46. Kartalou, M., Essigmann, J.M., Recognition of cisplatin adducts by cellular proteins. Mutat Res 478 (2001), 1–21.
47. Trimmer, E.E., Essigmann, J.M., Cisplatin. Essays Biochem. 34 (1999), 191–211.
48. Arany, I., Megyesi, J.K., Kaneto, H., et al. Cisplatin–induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol 287 (2004), F543–F549.
49. Campbell, K.C., Meech, R.P., Klemens, J.J., et al. Prevention of noise– and drug–induced hearing loss with D–methionine. Hear Res 226 (2007), 92–103.
50. Li, G., Sha, S.H., Zotova, E., et al. Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. Lab Invest 82 (2002), 585–596.
51. Lynch, E.D., Gu, R., Pierce, C., et al. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res 201 (2005), 81–89.
52. Garetz, S.L., Schacht, J., Ototoxicity: Of Mice and Men. Van de Water, T.R., Popper, A.N., Fay, R.R., (eds.) Clinical aspects of hearing, Springer handbook of auditory research, 7, 1996, Springer–Verlag, New York, xiv 317 p.
53. Schweitzer, V.G., Rarey, K.E., Dolan, D.F., et al. Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM–8) and CHIP (JM–9). Otolaryngol Head Neck Surg 94 (1986), 458–470.
54. Pasetto, L.M., D'Andrea, M.R., Brandes, A.A., et al. The development of platinum compounds and their possible combination. Crit Rev Oncol Hematol 60 (2006), 59–75.
55. Zhou, P., Qian, L., Kozopas, K.M., et al. Mcl–1, a Bcl–2 family member, delays the death of hematopoietic cells under a variety of apoptosis–inducing conditions. Blood 89 (1997), 630–643.
56. Wang, Y., Sun, X., Wu, J., et al. Casein kinase 1alpha interacts with RIP1 and regulates NF–kappaB activation. Biochemistry 47 (2008), 441–448.
57. Silvestrini, R., Veneroni, S., Daidone, M.G., et al. The Bcl–2 protein: a prognostic indicator strongly related to p53 protein in lymph node–negative breast cancer patients. J Natl Cancer Inst 86 (1994), 499–504.
58. Palacios, G., Moll, U.M., Mitochondrially targeted wild–type p53 suppresses growth of mutant p53 lymphomas in vivo. Oncogene 25 (2006), 6133–6139.
59. Park, H.H., Wu, H., Crystal structure of RAIDD death domain implicates potential mechanism of PIDDosome assembly. J Mol Biol 357 (2006), 358–364.
60. Tong, Q.S., Zheng, L.D., Wang, L., et al. Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther 12 (2005), 509–514.
61. Kelly, K.J., Plotkin, Z., Vulgamott, S.L., et al. P53 mediates the apoptotic response to GTP depletion after renal ischemia–reperfusion: protective role of a p53 inhibitor. J Am Soc Nephrol 14 (2003), 128–138.
62. Sax, J.K., El–Deiry, W.S., Identification and characterization of the cytoplasmic protein TRAF4 as a p53–regulated proapoptotic gene. J Biol Chem 278 (2003), 36435–36444.
63. Haupt, S., Berger, M., Goldberg, Z., et al. Apoptosis – the p53 network. J Cell Sci 116 (2003), 4077–4085.
64. Komarov, P.G., Komarova, E.A., Kondratov, R.V., et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285 (1999), 1733–1737.
65. Komarova, E.A., Gudkov, A.V., Chemoprotection from p53–dependent apoptosis: potential clinical applications of the p53 inhibitors. Biochem Pharmacol 62 (2001), 657–667.
66. Culmsee, C., Zhu, X., Yu, Q.S., et al. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta–peptide. J Neurochem. 77 (2001), 220–228.
67. Lakkaraju, A., Dubinsky, J.M., Low, W.C., et al. Neurons are protected from excitotoxic death by p53 antisense oligonucleotides delivered in anionic liposomes. J Biol Chem 276 (2001), 32000–32007.
68. Ishida, S., Lee, J., Thiele, D.J., et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99 (2002), 14298–14302.
69. Komatsu, M., Sumizawa, T., Mutoh, M., et al. Copper–transporting P–type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60 (2000), 1312–1316.
70. Lin, X., Okuda, T., Holzer, A., et al. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 62 (2002), 1154–1159.
71. Nakayama, K., Miyazaki, K., Kanzaki, A., et al. Expression and cisplatin sensitivity of copper–transporting P–type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines. Oncol Rep 8 (2001), 1285–1287.
72. Nitiss, J.L., A copper connection to the uptake of platinum anticancer drugs. Proc Natl Acad Sci USA 99 (2002), 13963–13965.
73. Saito, T., Moataz, R., Dulon, D., Cisplatin blocks depolarization–induced calcium entry in isolated cochlear outer hair cells. Hear Res 56 (1991), 143–147.
74. Saito, T., Yamamoto, T., Zhang, Z.J., et al. Transplatin blocks voltage–dependent calcium current in isolated cochlear outer hair cells but is not ototoxic in vivo. Brain Res 697 (1995), 276–279.
75. Vassilev, P.M., Kanazirska, M.P., Charamella, L.J., et al. Changes in calcium channel activity in membranes from cis–diammine–dichloroplatinum (II) –resistant and –sensitive L1210 cells. Cancer Res 47 (1987), 519–522.